Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Breast Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Breast Neoplasm

Cancer Family

Breast Neoplasm

CI-CAN-00000007Explore in graph →

Non-malignant2,895 active trials43 approved drugs310 evidence items

NCIt: C2910
OncoTree: BNNOS
MeSH: D000069584
MeSH: D001943

Overview
Statistics
Survival
Genomics33
Variants & evidence310
Drugs79
Trials13871
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (275)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 101–125 of 275 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.
· J Clin Oncol · 2025 · PMID 40845250 · validated civic_curation pubmed
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
· N Engl J Med · 2001 · PMID 11248153 · validated civic_curation pubmed
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
· J Clin Oncol · 2005 · PMID 15911866 · validated civic_curation pubmed
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
· N Engl J Med · 2015 · PMID 25693012 · validated civic_curation pubmed
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
· J Natl Cancer Inst · 2021 · PMID 32940689 · validated civic_curation pubmed
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
· Breast Cancer Res · 2021 · PMID 33579347 · validated civic_curation pubmed
Cyclin D1 in breast cancer pathogenesis.

Showing 101–125 of 275 publications

← Previous
1
…
4
5
6
…
11
Next →

· J Clin Oncol · 2005 · PMID 15961768 · validated civic_curation pubmed

Cyclin E and survival in patients with breast cancer.

· N Engl J Med · 2002 · PMID 12432043 · validated civic_curation pubmed

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.

· J Clin Oncol · 2011 · PMID 21422407 · validated civic_curation pubmed

FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.

· Ann Oncol · 2012 · PMID 22431701 · validated civic_curation pubmed

Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.

· J Clin Oncol · 2016 · PMID 26811533 · validated civic_curation pubmed

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

· J Clin Oncol · 2012 · PMID 22493419 · validated civic_curation pubmed

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

· Breast · 2015 · PMID 26255196 · validated civic_curation pubmed

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

· J Clin Oncol · 2010 · PMID 20124187 · validated civic_curation pubmed

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

· Lancet Oncol · 2016 · PMID 26822398 · validated civic_curation pubmed

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.

· Cancer Immunol Res · 2014 · PMID 24989892 · validated civic_curation pubmed

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

· N Engl J Med · 2006 · PMID 17192538 · validated civic_curation pubmed

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

· J Clin Oncol · 2009 · PMID 19289619 · validated civic_curation pubmed

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

· Lancet Oncol · 2014 · PMID 24793816 · validated civic_curation pubmed

Trastuzumab emtansine for HER2-positive advanced breast cancer.

· N Engl J Med · 2012 · PMID 23020162 · validated civic_curation pubmed

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

· J Clin Oncol · 2016 · PMID 27091708 · validated civic_curation pubmed

Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.

· Cancer Res · 2007 · PMID 17909070 · validated civic_curation pubmed

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

· N Engl J Med · 2012 · PMID 22149875 · validated civic_curation pubmed

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

· Lancet · 2012 · PMID 22257673 · validated civic_curation pubmed

Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.

· Cancer Res · 2013 · PMID 23204226 · validated civic_curation pubmed